Experimental drug tested for rare, Life-Threatening blood disorder
NCT ID NCT03205995
Summary
This study tested an experimental drug called OMS721 (narsoplimab) for adults and adolescents with atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage kidneys. The main goal was to see if the drug could safely increase platelet counts and control the disease over 26 weeks. The trial was small and ended early, enrolling only 6 participants who either didn't respond well to standard plasma treatments or couldn't use other available medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC-UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Chicago, Illinois, 60643, United States
-
Omeros Investigational Site
Vilnius, Lithuania
-
Omeros Investigational Site
Lodz, Poland
-
Omeros Investigational Site
New Taipei City, Taiwan
Conditions
Explore the condition pages connected to this study.